Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
Medtronic
McKesson
AstraZeneca
Johnson and Johnson

Last Updated: January 23, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for OSU-6162

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug OSU-6162?

OSU-6162 is an investigational drug.

There have been 6 clinical trials for OSU-6162. The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2012.

The most common disease conditions in clinical trials are Thrombosis, Neurofibromatosis 2, and Gliosarcoma. The leading clinical trial sponsors are Ohio State University, Massachusetts Eye and Ear Infirmary, and Stanford University.

There are thirteen US patents protecting this investigational drug and one hundred and twenty international patents.

Recent Clinical Trials for OSU-6162
TitleSponsorPhase
Evaluating the Relationship Between Tau PET Imaging and CSF Biomarkers of AD (Alzheimer Disease) in HumansWashington University School of MedicinePhase 2
Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and MeningiomaJohns Hopkins UniversityPhase 0
Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and MeningiomaMayo ClinicPhase 0

See all OSU-6162 clinical trials

Clinical Trial Summary for OSU-6162

Top disease conditions for OSU-6162
Top clinical trial sponsors for OSU-6162

See all OSU-6162 clinical trials

US Patents for OSU-6162

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
OSU-6162   Start Trial Centrally acting substituted phenylazacycloalkanes The Upjohn Company (Kalamazoo, MI)   Start Trial
OSU-6162   Start Trial Centrally actig substituted phenylazacycloalkanes The Upjohn Company (Kalamazoo, MI)   Start Trial
OSU-6162   Start Trial Treating fibromyalgia and chronic fatigue syndrome Pharmacia & Upjohn Company (Kalamazoo, MI)   Start Trial
OSU-6162   Start Trial Compounds for treating fibromyalgia and chronic fatigue syndrome Pharmacia & Upjohn Company (Kalamazoo, MI)   Start Trial
OSU-6162   Start Trial Method of treating and preventing migraine headaches Pharmacia & Upjohn Company (Kalamazoo, MI)   Start Trial
OSU-6162   Start Trial Treatments for restless legs syndrome Pharmacia & Upjohn Company (Kalamazoo, MI)   Start Trial
OSU-6162   Start Trial Method of treating parkinson's disease Pharmacia & Upjohn Company (Kalamazoo, MI)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for OSU-6162

Drugname Country Document Number Estimated Expiration Related US Patent
OSU-6162 Austria 201669 2011-04-17   Start Trial
OSU-6162 Australia 1986992 2011-04-17   Start Trial
OSU-6162 Australia 653837 2011-04-17   Start Trial
OSU-6162 Canada 2105666 2011-04-17   Start Trial
OSU-6162 Germany 69231854 2011-04-17   Start Trial
OSU-6162 Denmark 0641320 2011-04-17   Start Trial
OSU-6162 European Patent Office 0641320 2011-04-17   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Johnson and Johnson
Express Scripts
Colorcon
McKesson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.